C4A and systemic-onset juvenile idiopathic arthritis: This study aimed to investigate the trajectory of complement C3 and C4 levels during tocilizumab (TCZ) treatment in patients with systemic juvenile idiopathic arthritis (sJIA), explore the dynamic relationship between hypocomplementemia and disease activity, and characterize adverse events during long-term TCZ therapy.